<DOC>
	<DOCNO>NCT02284256</DOCNO>
	<brief_summary>The primary objective study demonstrate non-inferiority superiority Fibrocaps plus gelatin sponge compare Tachosil control mild moderate bleeding conventional surgical technique ineffective impractical .</brief_summary>
	<brief_title>A Safety Efficacy Study Comparing Fibrocaps Tachosil Hepatic Surgery</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria ( presurgery ) : 1 . Subject sign independent ethic committee ( IEC ) approve informed consent document 2 . Subject undergoing hepatic wedge resection anatomic resection 1 5 contiguous hepatic segment , and/or hepatic surgery , may combine surgical procedure involve gall bladder intestine 3 . Subject age &gt; 18 year time consent 4 . If female childbearing potential , subject negative pregnancy test screen breastfeed 5 . If subject sexually active male sexually active female childbearing potential , subject agrees use medically accept form contraception time consent completion followup study visit Inclusion Criteria ( surgery ) : 6 . Presence mild moderate bleeding/oozing control conventional surgical technique , include limited suture , ligature cautery ineffective impractical 7 . Absence intraoperative complication bleed , opinion investigator , may interfere assessment efficacy safety 8 . Approximate TBS surface area â‰¤ 100 cm^2 1 . Subject know hypersensitivity Fibrocaps components 2 . Subject know allergy porcine gelatin 3 . Subject know hypersensitivity Tachosil excipients include Tachosil 4 . Subject unwilling receive blood product 5 . Subject hepatic surgery due emergencytraumatic event 6 . Subject require extrahepatic bile duct resection ( common bile duct resection resection bile duct lead perform anastomosis bile duct small bowel ) biliary anastomosis , and/or pancreatic resection 7 . Subject clinicallysignificant coagulation disorder may interfere assessment efficacy pose safety risk subject accord investigator , baseline abnormality international normalized ratio ( INR ) &gt; 2.5 activate partial thromboplastin time ( aPTT ) &gt; 100 second screen explain current drug treatment ( e.g. , warfarin , heparin ) 8 . Subject platelet count &lt; 100 x10^9 PLT/L screen 9 . Subject medical , social psychosocial factor , opinion investigator , could impact safety compliance study procedures 10 . Subject currently participate participate another clinical study involve another investigational agent within 4 week plan date surgery planning participation another clinical trial within 6 week surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>